Global Blood Therapeutics, Inc.
GBT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $1,842 | $2,656 | $4,636 | $2,100 |
| - Cash | $685 | $495 | $302 | $275 |
| + Debt | $660 | $154 | $75 | $0 |
| Enterprise Value | $1,817 | $2,315 | $4,409 | $1,824 |
| Revenue | $195 | $124 | $2 | $0 |
| % Growth | 57.3% | 5,773% | – | – |
| Gross Profit | $191 | $122 | $2 | $0 |
| % Margin | 98.3% | 98.4% | 97.7% | – |
| EBITDA | -$279 | -$227 | -$257 | -$170 |
| % Margin | -143% | -183.3% | -12,183.8% | – |
| Net Income | -$303 | -$248 | -$267 | -$174 |
| % Margin | -155.6% | -200% | -12,654.9% | – |
| EPS Diluted | -4.82 | -4.04 | -4.57 | -3.41 |
| % Growth | -19.3% | 11.6% | -34% | – |
| Operating Cash Flow | -$257 | -$212 | -$194 | -$135 |
| Capital Expenditures | -$3 | -$9 | -$3 | -$5 |
| Free Cash Flow | -$260 | -$221 | -$198 | -$140 |